News

Keep up to date with CTx announcements, press releases and general news items

By CTxadmin
 • 
2 months ago

Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer will gain the rights to two novel pre-clinical cancer programs and CTx will receive US$14.2 million [AUD$20M] upfront …
Read More

By CTxadmin
 • 
2 months ago

Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high unmet need he has led his organisation from the licensing of moxidectin, an abandoned drug development …
Read More

By CTxadmin
 • 
3 months ago

Of the 129 children enrolled in the trial from across Australia with high-risk and relapsed cancers, 67% were provided with personalised treatment plans aimed at killing their unique cancer cells. For most children enrolled in the trial, there were otherwise few to no treatment options …
Read More

By CTxadmin
 • 
4 months ago

This unique free full-day symposium, a collaboration between Cancer Therapeutics CRC (CTx), Merck Sharp & Dohme (MSD), and the Victorian Comprehensive Cancer Centre (VCCC), brings together leading industry, academic and clinical experts to discuss opportunities to progress biological discoveries to effective therapies, covering cancer drug discovery, …
Read More

By CTxadmin
 • 
5 months ago

In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies.
Published today in the journal Nature, the research reveals the first class …
Read More

By CTxadmin
 • 
7 months ago

Cancer Therapeutics CRC (CTX), a small molecule oncology drug discovery and development group partnered with some of Australia’s pre-eminent medical research institutions, is pleased to announce two Focal Adhesion Kinase (FAK) targeting drug candidates originally developed by CTX have been acquired by Innate Immunotherapeutics Ltd …
Read More